Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Adverse drug reactions

EMA takes on responsibility for screening medical literature for ADRs

The European Medicines Agency (EMA) has taken over responsibility for screening selected medical literature for suspected adverse drug reactions (ADRs) associated with certain drug substances. Previously, it was down to pharmaceutical companies to scour the literature and to report any suspected ADRs to EudraVigilance, the EU’s pharmacovigilance database.

The new service is being offered to pharmaceutical companies to help them meet their reporting obligations under EU pharmacovigilance regulations. The EMA believes the new system will improve safety monitoring and reduce the duplication of ADR reports made because active substances are included in more than one medicine.

The agency has published a list of the 400 substance groups that it will monitor and the medical literature that it will screen as part of the service, which is focusing on substances that are contained in lots of medicines. The service, which is being outsourced by the EMA, will start with a limited number of active substances on 1 July 2015 and is expected to be fully operational by September 2015.

Databases of medical literature covered by the service include EMBASE, an indexed biomedical reference database that is updated daily, and EBSCO, which includes Medline Plus, International Pharmaceutical Abstracts (IPA) and the Allied and the Complementary Medicine Database (AMED). Pharmaceutical companies will continue to be responsible for monitoring all other medical literature and for monitoring drug substances not included in the service and reporting any suspected ADRs identified.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068549

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.